Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
종목 코드 CSTL
회사 이름Castle Biosciences Inc
상장일Jul 25, 2019
CEOMaetzold (Derek J)
직원 수761
유형Ordinary Share
회계 연도 종료Jul 25
주소505 S Friendswood Drive
도시FRIENDSWOOD
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호77546
전화18667889007
웹사이트https://castlebiosciences.com/
종목 코드 CSTL
상장일Jul 25, 2019
CEOMaetzold (Derek J)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음